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tion< 1.2%). The repetitions of kV,mA,mAs were in normal range (derivation coef-
ficient< 0.01 ). Image resolution was acceptable (1.4-3.1 lp/mm). ConClusions: 
Review of this study I observed following problems such as we use and installed 
the oldest equipments from other countries, those were worked over than 10 years; 
spare parts were not manufactured; not installed software for measurement and 
process of patients and angiographic staff x-ray doses; not having optional units 
for evaluating and fixing image quality; quality control performance is made by 
Nuclear Energy Agency of Mongolia just one time a year; not acceptance of image 
processing, delivering and printing system. Therefore, more important things are 
in this field are development and renovation of equipments.
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health caRe Use & Policy stUdies – consumer Role in health care
PhP1
FactoRs aFFecting the selection oF soRe thRoat lozenge 
oF dRUgstoRe’s cUstomeR at nakoRnPathom mUniciPality, 
nakoRnPathom PRovince, thailand
Kaewpratum Y., Liyeeke W., Taveesiriwet S., Kanchanapornchai S., Maitreemit P.
Silpakorn university, Nakorn Pathom, Thailand
objeCtives: The aim of this research was finding the factors affect the decision of 
customers in drug stores for selecting the sore throat lozenges. Methods: Survey 
research had been conducted since October to November 2012. The data had been 
collected by using questionnaires from 410 buyers age over 15 years who request the 
sore throat lozenges in drugstores for themselves. Results: Most of respondents 
were women (71.46%), aged 15-25 years old (30.49%), hold bachelor degree (40.73%), 
students (25.12%), no monthly income (27.80%) and had no income (27.80%). Most 
of them used to buy modern medicine types of sore throat lozenges (68.78%) more 
than traditional medicine type (21.22%). Their objectives were for reducing sore throat 
(36.35%) follow by reducing throat irritation (23.97%), reducing cough (19.95%) and 
expectorant (9.98%) respectively. Most of them would buy the modern medicine in 
the next time (69.27%). The level of decision making using available factor and infor-
mation factor were in high level, the price factor and product factor were in medium 
level. The relationship between gender and gender and former using on selecting the 
types of sore throat lozenges were statistical significance of 0.05 levels. The factors 
influenced the selection of sore throat lozenges were 1) Place factor (= 4.02±1.81) espe-
cially selecting from availability and convenience was in the high level, 2) Information 
factor (= 3.60±0.33) especially selecting by using their information and receiving the 
information from health professions were in the high level, receiving the information 
from the various medias and the intimate persons were in the medium level. 3) Price 
factor (= 3.44±0.18) especially selecting from appropriateness to severity was in the 
high level. 4) Product factor (= 3.18±0.50) especially selecting from taste was in the 
high level (= 4.02±1.81). ConClusions: The results could be applied by community 
pharmacists in advising the customers for sore throat lozenges selection and the 
manufacturers or marketing managers in producing and distributing their products.
PhP2
assesing the imPact oF Patent loss on oveRall RevenUes and stocks 
PRice oF PhaRmaceUtical comPanies
Furnback W., Wang B.C.M.
Alliance Life Sciences, Somerset, NJ, USA
objeCtives: With the pre-tax R&D cost of bringing a biopharmaceutical product 
to market estimated at $1.2 billion, revenues from blockbuster drugs may need to 
cover the development cost of multiple drugs. We analyzed four major blockbuster 
products that lost patent between 2011 and 2012 and the associated change in 
sales it had on the company. Methods: We identified four major products (ator-
vastatin, clopidogrel, quetiapine, and montelukast) that lost patent protection 
between 2011 and 2012. Then, we retrieved sales data for the drug, total revenue, 
and stock price for the company from Q1 2011 to Q4 2013. Sales data was from IMS 
Health via drugs. com. Total company revenue per quarter was provided by Charles 
Schwab & Co. and historical stock data was taken from Yahoo! Finance. Results: 
During the time the drugs were under patent, they made up an average of 16.8% 
of total revenues per quarter. Total sales for the four drugs were down an average 
of 78.8% by Q4 2013 while total revenues for the companies were only down on 
average 11.9%. Stock prices over the same period increased an average of 72.5%. 
During the time the product had patent protection, the stock prices of those four 
companies increased at an average of 3.7% per quarter, as opposed to the 5.8% 
increase per quarter when the patent expired. During patent protection, aver-
age company revenue grew at an average of 1.52% per quarter; when the patent 
expired, revenue declined at an average of 1.9%. ConClusions: Overall these 
blockbuster drugs do not seem to significantly decrease revenues and do not 
influence stock prices when their patent protection is up. Large pharmaceuticals 
may reinvest profits to bolster their pipelines and find replacements for these 
large-revenue drugs. Investors seem to appropriately price in patent expiration 
into stock prices long before the actual event.
health caRe Use & Policy stUdies – diagnosis Related group
PhP3
the PeRFoRmance- volUme limit decReased the dRg Based acUte caRe 
hosPital Financing in hUngaRy
Endrei D.1, Decsi T.1, Gazsó T.1, Ágoston I.1, Csákvári T.2, Kovács G.3, Boncz I.1
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary, 3Széchenyi István 
University, Győr, Hungary
these patients suffered greater pain and lower HRQoL than nociceptive pain patients. 
The more remarkable improvement NP patients showed after treatment highlights 
the importance of appropriate diagnosis and treatment of NP.
systemic disoRdeRs/conditions – Patient-Reported outcomes & Patient 
Preference studies
Psy9
PRicing and maRket access oF oRPhan dRUgs in asia: a comPaRative 
stUdy acRoss gRowth maRkets
Sherwin G.1, Akpinar P.1, Saraf S.1, Li X.2
1ICON Pricing and Market Access, London, UK, 2ICON Commercialisation & Outcomes, London, UK
objeCtives: With the majority of the world’s population and considerably high 
GDP growth rates, Asia represents a significant opportunity for commercialization 
of orphan drugs (OD) for rare diseases. However, despite some countries implement-
ing policy to facilitate this process, funding for ODs remains challenging due to 
conflicting priorities with coverage of essential medicines. We aimed to understand 
the current coverage policies for ODs in China, Taiwan, Singapore and South Korea, 
and evaluate the impact they have on pricing and market access. Methods: We 
conducted secondary research of government legislation in each country to identify 
specific policy and decision making criteria for coverage of ODs and rare diseases. 
We also selected 8 ODs and scored them based on a pre-defined set of access drivers 
(incidence of the disease, severity of the condition, therapeutic alternatives, level of 
innovation, affordability, etc.). Finally, we analyzed the scores to identify any cor-
relation with the pricing and reimbursement status of these drugs in each market, 
and considered the influence of any identified policies on the results. Results: 
National legislation for OD coverage was identified in Taiwan, Singapore and South 
Korea; however, the degree to which policy influences coverage varies considerably 
between countries. Additionally, in the absence of national legislation in China, 
provincial policies do exist, albeit infrequently and with considerable disparity. 
Scores for access drivers were minimally correlated with pricing and reimbursement 
status, however, high scores were not necessarily indicative of positive coverage; 
rather, affordability is the primary driver for access. ConClusions: Our results 
demonstrate that, although there is considerable market opportunity supported 
by variable legislation to facilitate OD coverage, pricing and market access remains 
challenging and is not necessarily related to individual product value. Therefore, 
pharmaceutical companies seeking access for ODs should consider selective pro-
grams, designed to improve affordability and patient access.
Psy10
the socioeconomic costs oF the UndeRtReatment oF Pain
Hopp M.1, Bosse B.1, Dunlop W.2
1Mundipharma Research GmbH & Co. KG, Limburg, Germany, 2Mundipharma International 
Limited, Cambridge, UK
objeCtives: To investigate the scale and socioeconomic cost of untreated/uncon-
trolled chronic pain. Methods: We performed a systematic literature search in 
PubMed to identify studies reporting the economic cost of pain globally and in Asia 
Pacific. Results: Prevalence estimates for chronic pain among adults range from 
2-40% in the US and 12-30% in Europe, with similar rates reported in Hong Kong 
(10.8%) and Singapore (8.7%). Chronic pain is costly not only because it requires 
medical treatment and complicates treatment for other conditions, but because 
it undermines the ability to lead a productive working and social life, placing a 
substantial burden on individuals, employers, health care systems and societies in 
general. Despite the personal and socioeconomic impact of chronic pain, a large pro-
portion of patients remain untreated. A third of chronic pain patients in a European 
survey were currently not treated, while around half of patients with cancer pain 
are undertreated. Poor availability of medications due to cost, licensing, prescribing 
regulations, lack of training for health care workers and cultural factors are causes 
of undertreatment, especially in the developing world. The majority of countries in 
Asia have limited or very limited availability of medicines for moderate to severe 
pain and no national palliative care policies. The costs associated with chronic pain 
in terms of direct health care and indirect costs are huge, estimated at $560-635 
billion annually in the US and as much as € 300 billion in Europe, and representing 
3-10% of gross domestic product. Chronic pain therefore represents an economic 
burden at least as great as priority health conditions such as heart disease, cancer 
and diabetes. ConClusions: A strategic approach is required to counter the unac-
ceptable burden of uncontrolled chronic pain at the national and international level, 
alongside further research and education into effective treatment, management 
and prevention of pain.
Psy11
stUdy oF technical conditions FoR imPRovement oF angiogRaPhic 
image QUality
Myagmarnaran T.1, Oyunaa C.2, Odongua N.3
1School of Nursing, Health Science University of Mongolia, Ulaanabaatar, Mongolia, 2School of 
Nursing, Health Science University of Mongolia, Ulaanbaatar, Mongolia, 3School of Nursing, 
Health Science University of Mongolia, Ulaanbaatar, Mongolia
objeCtives: The purpose of this study was to explore the quality of angiography 
equipment in diagnosis and treatment used in Mongolia, compare the use of angi-
ography in Mongolia to international standards, type and number of angiography 
examinations, radiologist and patient’s health safety from the effects of X-rays, 
and the study the benefits of the quality control tests of X-rays and how they affect 
image quality and other factors. Methods: By experimental method, used an 
ionization chamber and test object for x-ray image quality to assess angiographic 
image quality based on The Mongolian National Standard MNS 5391:2004. A total 
of 5 angiographies were studied. Measurement acceptance of kV assurance, linear-
ity, repetition of kV,mA,mAs, image resolution were not higher 5% from reference 
values. Results: Standard derivation of kV assurance was moderate (St.deriva-
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objeCtives: To explore the impact of market competition on pharmaceutical pric-
ing, and to further investigate the determinants of pharmaceutical price in Chinese 
pharmaceutical market. Methods: Anti-infective pharmaceutical data were 
extracted from inpatient claims in Tianjin Urban Employee Basic Medical Insurance 
(UEBMI) database from 2006 to 2010. Based on product-quarter data, a quasi-hedonic 
regression model was used to estimate the impact of market competition, which 
is defined by generic competition (the number of manufacturers within the same 
generic market) and therapeutic competition (the number of molecules in the ATC3 
therapeutic category). The inputs to our model were specific attributes of the products 
and manufacturers, with the exception of competition variables. Defined daily dose 
(DDD) was used as the standard quantity unit and the price per DDD was used as the 
price unit. Results: Our results indicated that pharmaceutical prices were inversely 
related to the number of generic competitors, but positively related to the number 
of therapeutic competitors. The prices of patent drugs and the off-patent drugs from 
original manufacturer were significantly higher than the prices of generic drugs. 
We also found the positive relationship between DDD and price, and the negative 
relationship between pack size and price which implied that manufacturers com-
pete on volume discounts on large pack size. In addition, product age was inversely 
related to product price. In terms of manufacturers’ attributes, the results suggested 
that the prices of products imported by the foreign manufacturers and produced by 
joint-venture firms were higher than those of products from local manufacturers, and 
the prices of products from domestic 100 top-selling manufacturers were lower than 
those of products from non-top 100 local manufacturers. ConClusions: Generic 
market competition still plays an important role in determination of regulated phar-
maceutical prices in China. The drug attributes, manufacturers’ attributes and market 
competition are jointly determined pharmaceutical price.
PhP7
PRice comPaRison Between the essential and non-essential  
anti-inFective medicines among national ReimBURsement  
dRUg list in china
Ma F.F., Wu J., Zhao M.Y.
Tianjin University, Tianjin, China
objeCtives: To compare the price changes of the essential and the non-essential 
anti-infective medicines in Tianjin, China using index method. Methods: Data were 
extracted from inpatient claims in Urban Employee Basic Medical Insurance data-
base of Tianjin, China, from 2006 to 2010. Price indices were measured by Fisher and 
chained Fisher index formulas by quarter. The quantity weight unit was defined daily 
dose (DDD) and the price unit was the price per DDD. Price indices were calculated 
both at molecule level (defined by active ingredient) and product level (defined by 
molecule, strength, preparation, and manufacturer). Results: The data contained 
41 molecules and 786 products among the essential anti-infective medicines, and 81 
molecules and 636 products among the non-essential anti-infective medicines. For 
the essential anti-infective medicines, the price index decreased to 0.90 (in chained 
Fisher index at molecule level) from 2006 Q1 to 2010 Q4, and the price index for the 
non-essential anti-infective medicines decreased to 0.73 (in chained Fisher index 
at molecule level) during the same period. For the essential and non-essential anti-
infective, the results of chained Fisher and unchained counterparts were similar 
(10% vs. 10% for the essential and 28% vs. 27% for the non-essential at molecule 
level). The price indices at molecule level decreased slower than the counterparts at 
product level (10% vs. 24% for the essential and 27% vs. 30% for the non-essential in 
chained Fisher index). ConClusions: The price of the essential and non-essential 
anti-infective medicines among national reimbursement drug list had decreased in 
Tianjin, China, but the price of the essential anti-infective medicines decreased slower 
than the non-essential anti-infective medicines.
PhP8
imPact oF dRUg Policy on imPRoving access to medicines in delhi
Bhoi N.
IPE Global, DFID supported Health Sector Reforms Programme, Bhubaneshwar, India
objeCtives: To assess the impact of drug policy on improving access to essential 
medicines in Delhi Methods: The quantity of drugs procured from the Essential 
Drugs List (EDL) and outside the EDL; money spent on these; changes in stock out 
days for the key drugs. The implementation strategy includes elements of drug 
policy like use of EDL & STG, improved procurement system, training on drugs 
management & rational use of drugs. Retrospective data collected from stock reg-
isters. The data for two years before (1993-1994, 1994-1995) and two years after 
(2000-2001, 2001-2002) the drug policy was assessed. Data collected from two large 
public sector hospitals in Delhi that serve a large section of the population through 
convenient purposive sampling method. Results: After the implementation of 
the drug policy, the availability of drugs increased by 25% in the large and 98% in 
the medium hospital. The drugs procured from the EDL increased from 62% to 78% 
in the large and 74% to 87% in the medium hospital. Of the total expenditure, the 
money spent on essential drugs increased from 73% to 85% in the large and 87% to 
93% in the medium hospital, whereas money spent on nonessential drugs decreased 
from 27% to 15% in the large and 13% to 7% in the medium hospital. The average 
number of stock out days for key dugs decreased from 33 to 16 days in the large 
and from 143 days to 33 days in the medium hospital. The utilization pattern of 
health services by patients increased by 8% in the large and by 35% in the medium 
hospital. ConClusions: The implementation of the drug policy in the state of 
Delhi increased availability of essential drugs. This kind of intervention can serve 
as a model for improving access to medicines by implementing an effective drug.
PhP9
the imPact on dRUg PRice and Patient selection oF national 
essential dRUg system: evidence FRom inPatient RecoRds FRom 
insURance ReimBURsement data
Du N., Xu J.
Southwest University of Finance and Economics, chengdu, China
objeCtives: Diagnosis related groups (DRG) like financing method was introduced in 
Hungary in 1993 for acute care hospital reimbursement. Due to the increased activity 
of the hospitals, an upper ceiling, the so called performance volume limit (PVL) was 
introduced in acute care hospital financing in 2004. The aim of our study was to ana-
lyze the effect of performance volume limit on DRG based hospital financing on the 
example of a Hungarian tertiary teaching hospital, the Clinical Centre of the University 
of Pécs. Methods: Data derived from the financial database of the National Health 
Insurance Fund Administration, the only health care financing agency in Hungary. 
We analyzed the proportion of hospital activity over the performance volume limit 
ceiling. We calculated the proportion of hospital activity over that ceiling measured by 
DRG cost-weights. The period 2004-2013 was involved into the study. Results: The 
annual number of patients varied between 72671 (2007) and 82509 (2009) at the Clinical 
Centre of the University of Pécs. During the same period the annual performance 
volume limit for DRG costweigths varied between 97784 and 116970. However due to 
the regulation of the upper ceiling of hospitals’ activity, 3.0 % (2007) to 14.9 % (2009) of 
that activity has not been reimbursed to the Clinical Centre. The average loss of reim-
bursement due to performance volume limit was 7.2 % of annual revenues between 
2004-2013. ConClusions: The introduction of performance volume limit into the 
DRG based hospital financing resulted in a partial loss of hospitals’ revenues. Despite 
of in PVL regulation, the Clinical Centre of the University of Pécs did not reduced its 
output, thus the annual number of patients did not declined in this hospital.
health caRe Use & Policy stUdies – disease management
PhP4
co-administRation oF tURmeRic Potentiates PReventive eFFect oF 
Black seeds in metaBolic syndRome
Gilani A.H., Amin F., Mehmood M.H.
The Aga Khan University, Karachi, Pakistan
objeCtives: The metabolic syndrome (MS), a combination of metabolic abnormali-
ties including obesity, diabetes, dyslipidemia and hypertension is associated with 
an increased risk of coronary heart disease and stroke. Complementary medicines 
including herbs like Turmeric and Black seeds (Nigella sativa) can be used to pre-
vent or as an adjuvant to control MS with fewer side-effects, better acceptability 
and cost effectiveness. This study determines if the co-administration of Turmeric 
potentiates the beneficial effects of black seeds on MS in rats. Methods: Black seeds 
and Turmeric alone and in combination at different dosages were administered to 
fructose-fed rats. Blood pressure, fasting sugar and lipid profile were measured 
before and after 3 and 6 weeks of treatment. Serum insulin and endothelial func-
tion were determined at 6 weeks of intervention Results: Black seeds at the dose 
of 0.6 g/kg prevented hypertension at week 3 of intervention, while at 6 weeks it 
prevented hypertension, hyperglycemia, dyslipidemia and endothelial dysfunction. 
Turmeric at 3 g/kg dose prevented dyslipidemia but not hypertension. The combi-
nation of 0.3 g/kg Black seeds and 1.5 g/kg Turmeric prevented hypertension and 
hypertriglyceridemia at week 3 but provided a wide coverage at 6 weeks including in 
hypertension, hyperglycemia, dyslipidemia, hyperinsulinemia and endothelial dys-
function. ConClusions: This study showed that co-administration of Turmeric and 
Black seeds resulted in enhanced efficacy in correcting metabolic syndrome when 
compared with each component used alone, while the reduced dose of individual 
component when used in combination is likely to reduce the side-effects.
PhP5
PhaRmacological Basis FoR the medicinal Use oF almonds in 
caRdiovascUlaR disoRdeRs
Gilani A.H.1, Jamshed H.2
1The Aga Khan University, Karachi, Pakistan, 2Department of Biological and Biomedical Sciences, 
The Aga Khan University, Karachi, Pakistan
objeCtives: Though almonds are shown to be effective in cardiovascular disorders 
(CVDs), but there is limited information on the possible mode of action. This study 
aimed at exploring, in multiple rat models, the pharmacological basis for the medici-
nal use of almonds in CVDs. Methods: Tyloxapol, high-fat diet (HFD) and fructose 
models were used. Group 1 in each study was normal control and group 2 and 3 were 
diseased groups. Almonds were given for four weeks to group 3 of each study, after 
which blood was collected for biochemical estimations. Liver from rats of tyloxapol 
study and thoracic aorta from rats of HFD study were isolated for enzyme assays and 
vascular reactivity. Results: Almonds supplementation significantly (p < 0.05) pre-
vented hyperlipidemia in all the three rat models. In tyloxapol-induced hyperlipidemia 
model, almond supplementation inhibited HMG-CoA activity. It also improved lipid 
profile and prevented HFD-induced increase in serum biomarkers of liver dysfunc-
tion (amino-transferases) and endothelial dysfunction (uric acid, phosphorus, alkaline 
phosphatase and gamma glutamyl transferase) as well as restored endothelial reac-
tivity. Almonds also demoted the HFD-induced inhibition of endothelial nitric oxide 
synthase enzyme, thereby, promoting serum nitric oxide release. In the fiber-free while 
flour with fructose model, improvement in serum HDL was observed, in addition to 
improvement in other markers of lipid abnormality. ConClusions: Almond sup-
plementation demonstrated cardio-protection and antidyslipidemic effect mediated 
through multiple pathways including inhibition of cholesterol synthesis and restora-
tion of hepatic and endothelial function, while the use of multiple animal models aided 
in gaining insights on some of the possible mechanism of actions.
health caRe Use & Policy stUdies – drug/device/diagnostic Use & Policy
PhP6
PhaRmaceUtical PRicing and maRket comPetition: an emPiRical 
stUdy Based on anti-inFective dRUgs in tianjin, china
Zhao M.Y., Wu J., Ma F.F.
Tianjin University, Tianjin, China
